Rigel Pharmaceuticals Inc (RIGL)

NASDAQ
Currency in USD
20.440
-0.080(-0.39%)
Real-time Data·
RIGL Scorecard
Full Analysis
Valuation implies a strong free cash flow yield
RIGL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.31021.512
52 wk Range
7.48429.820
Key Statistics
Edit
Prev. Close
20.52
Open
20.55
Day's Range
20.31-21.512
52 wk Range
7.484-29.82
Volume
32.72K
Average Volume (3m)
215K
1-Year Change
115.32%
Book Value / Share
1.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RIGL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.742
Upside
+65.08%
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year

Rigel Pharmaceuticals Inc News & Analysis

Show more

Rigel Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Employees
163

Rigel Pharmaceuticals Inc SWOT Analysis


Pipeline Promise
Explore Rigel's R289 and fostamatinib candidates, showing potential in MDS and sickle cell disease, driving future growth prospects
Financial Turnaround
Rigel achieves positive net income, showcasing strong revenue growth and effective expense management in hematology and oncology sectors
Market Positioning
Delve into Rigel's strategy of leveraging commercial success to fund pipeline development, balancing current products with future innovations
Analyst Outlook
Price targets range from $15 to $57, reflecting diverse views on Rigel's growth potential in the competitive biotech landscape
Read full SWOT analysis

Rigel Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue up 68% YoY to $53.3M; net income of $11.4M vs $8.2M loss in Q1 2024
  • Stock surged 18.02% in aftermarket trading to $21.55; TAVALISSE sales grew 35% YoY
  • 2025 revenue guidance set at $200-210M; company expects positive net income for full year
  • Focus on expanding commercial portfolio and advancing R289 for MDS and elutacitinib for glioma
  • Strong financial health with 76.5% gross profit margin and 2.13 current ratio
Last Updated: 07-05-2025, 03:00 am
Read Full Transcript

Compare RIGL to Peers and Sector

Metrics to compare
RIGL
Peers
Sector
Relationship
P/E Ratio
9.9x−1.5x−0.5x
PEG Ratio
0.030.000.00
Price/Book
19.7x1.2x2.6x
Price / LTM Sales
1.8x4.0x3.1x
Upside (Analyst Target)
14.5%498.6%51.1%
Fair Value Upside
Unlock30.2%8.9%Unlock

Analyst Ratings

2 Buy
4 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 33.742
(+65.08% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
0.63 / -0.02
Revenue / Forecast
53.33M / --
EPS Revisions
Last 90 days

RIGL Income Statement

FAQ

What Is the Rigel (RIGL) Stock Price Today?

The Rigel stock price today is 20.44.

What Stock Exchange Does Rigel Trade On?

Rigel is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Rigel?

The stock symbol for Rigel is "RIGL."

What Is the Rigel Market Cap?

As of today, Rigel market cap is 369.07M.

What Is Rigel's Earnings Per Share (TTM)?

The Rigel EPS (TTM) is 2.11.

From a Technical Analysis Perspective, Is RIGL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Rigel Stock Split?

Rigel has split 2 times.

How Many Employees Does Rigel Have?

Rigel has 163 employees.

What is the current trading status of Rigel (RIGL)?

As of 16 Jun 2025, Rigel (RIGL) is trading at a price of 20.44, with a previous close of 20.52. The stock has fluctuated within a day range of 20.31 to 21.51, while its 52-week range spans from 7.48 to 29.82.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.